News No benefit of low dose apixaban following acute COVID-19 By December 15, 202231 views ShareTweet 0 AI nuclear energy background, future innovation of disruptive technology The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.
Cervical cancer burden remains high in many countries; scale-up needed to meet 2030 elimination target
Study: Latinx students experienced higher rates of depression and anxiety during the pandemic By 19 hours ago0
Groundbreaking technique offers a new way to gain detailed information about organic tissues By 19 hours ago0
New statistical model could help doctors improve outcomes for pediatric tonsillectomies 19 hours ago0
New microfluidic device quickly and automatically predicts the effectiveness of cancer treatment 24 hours ago0
By 
Comments